SML3478
PNU-159682
≥95% (HPLC)
别名:
(8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[(1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano[4′,3′:4,5]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy]-5,12-naphthacenedione, PNU 159682
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C32H35NO13
化学文摘社编号:
分子量:
641.62
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
assay
≥95% (HPLC)
form
powder
storage condition
under inert gas
color
, Faint red to very dark red
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Highly potent anthracycline toxin
PNU-159682, an active nemorubicin metabolite, is a highly potent anthracycline toxin that retains antitumor activity in vivo. Similarly to other anthracyclines PNU-159682 intercalates between the CG base pairs of DNA, but the stability of the complexes is much higher.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Carc. 2 - Muta. 2 - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Stefania Mazzini et al.
Bioorganic & medicinal chemistry, 20(24), 6979-6988 (2012-11-17)
The antitumor anthracycline nemorubicin is converted by human liver microsomes to a major metabolite, PNU-159682 (PNU), which was found to be much more potent than its parent drug toward cultured tumor cells and in vivo tumor models. The mechanism of
Luigi Quintieri et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 11(4), 1608-1617 (2005-03-05)
Nemorubicin (3'-deamino-3'-[2''(S)-methoxy-4''-morpholinyl]doxorubicin; MMDX) is an investigational drug currently in phase II/III clinical testing in hepatocellular carcinoma. A bioactivation product of MMDX, 3'-deamino-3'',4'-anhydro-[2''(S)-methoxy-3''(R)-oxy-4''-morpholinyl]doxorubicin (PNU-159682), has been recently identified in an incubate of the drug with NADPH-supplemented rat liver microsomes. The aims
Nikolas Stefan et al.
Molecular cancer therapeutics, 16(5), 879-892 (2017-03-05)
Antibody-drug conjugates (ADC) are highly potent and specific antitumor drugs, combining the specific targeting of mAbs with the potency of small-molecule toxic payloads. ADCs generated by conventional chemical conjugation yield heterogeneous mixtures with variable pharmacokinetics, stability, safety, and efficacy profiles.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持